Jazz Pharmaceuticals Holds Shareholder Vote

TL;DR

Jazz Pharma held a shareholder vote on 7/25, details TBD.

AI Summary

On July 25, 2024, Jazz Pharmaceuticals plc filed an 8-K report indicating that matters were submitted to a vote of security holders. The filing does not disclose the specific proposals voted on or the outcome of the vote.

Why It Matters

This filing signals a corporate governance event where shareholders exercised their voting rights on company matters. The specifics of the vote are not detailed in this initial report.

Risk Assessment

Risk Level: low — The filing is a routine procedural report of a shareholder vote without immediate financial implications or disclosed negative outcomes.

Key Players & Entities

• Jazz Pharmaceuticals plc (company) — Registrant
• July 25, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.0001 — stered Ordinary shares, nominal value $0.0001 per share JAZZ The Nasdaq Stock Marke

Filing Documents

• jazz-20240725.htm (8-K) — 48KB
• 0001232524-24-000056.txt ( ) — 177KB
• jazz-20240725.xsd (EX-101.SCH) — 2KB
• jazz-20240725_lab.xml (EX-101.LAB) — 23KB
• jazz-20240725_pre.xml (EX-101.PRE) — 13KB
• jazz-20240725_htm.xml (XML) — 3KB

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. Results of Matters Presented at the 2024 Annual General Meeting of Shareholders On July 25, 2024, we held our 2024 annual general meeting of shareholders, or the Annual Meeting, at our corporate headquarters located at Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland. At the Annual Meeting, our shareholders voted on five proposals, each of which is described in more detail in our definitive proxy statement on Schedule 14A as filed with the SEC on June 14, 2024, or the Proxy Statement. The results of the matters presented at the Annual Meeting, based on the presence in person or by proxy of holders of 58,033,376 of the 63,062,356 ordinary shares entitled to vote, are described below. Proposal 1 Proposal 1 was to elect by separate resolutions each of the four nominees for director named below to hold office until our 2027 annual general meeting of shareholders. Each of the four nominees for director was elected as follows: Director Nominees For Against Abstain Broker Non-Votes Laura J. Hamill 52,774,330 1,432,999 133,482 3,692,565 Patrick Kennedy 52,306,399 1,901,706 132,706 3,692,565 Kenneth W. O'Keefe 50,931,857 3,280,188 128,766 3,692,565 Mark D. Smith, M.D. 50,507,449 3,685,604 147,758 3,692,565 Proposal 2 Proposal 2 was to ratify, on a non-binding advisory basis, the appointment of KPMG, Dublin as our independent auditors for the fiscal year ending December 31, 2024 and to authorize, in a binding vote, our board of directors, acting through the audit committee, to determine the auditors' remuneration. This proposal was approved as follows: For Against Abstain Broker Non-Votes 56,719,225 1,184,200 129,951 — Proposal 3 Proposal 3 was to approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement. This proposal was approved as follows: For Against Abstain Broker Non-Votes 49,319,464 4,780,265 241,082

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY By: /s/ Neena Patil Name: Neena Patil Title: Executive Vice President and Chief Legal Officer Date: July 26, 2024

View Full Filing

View this 8-K filing on SEC EDGAR